Tavneos (avacopan) / Amgen 
Welcome,         Profile    Billing    Logout  
 5 Diseases   7 Trials   7 Trials   708 News 


«123456789»
  • ||||||||||  Tavneos (avacopan) / Kissei, Vifor, ChemoCentryx
    Journal:  Avacopan. (Pubmed Central) -  Feb 19, 2022   
    No abstract available
  • ||||||||||  Soliris (eculizumab) / AstraZeneca
    Journal:  Human Neutrophils Respond to Complement Activation and Inhibition in Microfluidic Devices. (Pubmed Central) -  Feb 17, 2022   
    We show that whereas complement factor 5 (C5) cleavage inhibitor eculizumab blocks all neutrophil anti-microbial functions, newer compounds like the C5 cleavage inhibitor RA101295 and C5a receptor antagonist avacopan inhibit chemotaxis and swarming while preserving neutrophil phagocytosis. These results highlight the utility of microfluidic neutrophil assays in evaluating potential complement-targeting therapeutics.
  • ||||||||||  Tavneos (avacopan) / Kissei, Vifor, ChemoCentryx
    Clinical, Review:  Journal Club Review of "Avacopan for the Treatment of ANCA-Associated Vasculitis". (Pubmed Central) -  Feb 16, 2022   
    P3
    Potential weaknesses of this study include the lack of rituximab maintenance as part of standard-of-care treatment beyond week 4 of induction therapy and complete wean off prednisone by week 21, much faster than steroid weans in prior trials (including PEXIVAS), which may somewhat limit our interpretation of the noninferiority of avacopan to prednisone. Overall, the ADVOCATE trial yielded thought-provoking clinical implications that may revolutionize AAV treatment moving forward, including less reliance on corticosteroids to achieve clinical remission in AAV.
  • ||||||||||  Tavneos (avacopan) / Kissei, Vifor, ChemoCentryx, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    Review, Journal:  Recent Advancements in the Management of Anti-neutrophil Cytoplasmic Antibody-Associated Vasculitis: A Systematic Review. (Pubmed Central) -  Feb 15, 2022   
    Rituximab, avacopan, corticosteroids, including intravenous pulse methylprednisolone, plasma exchange, and immunological targeting are among the emerging treatments...The authors explored multiple databases, employing appropriate keywords, satisfying the quality appraisal, after which a total of 14 reports were included in this review. Upon overall analysis, it can be concluded that rituximab and CYC, when used in combination, provided a safer alternative to GCs while exhibiting equal, if not superior, effectiveness and results, thus, paving the way for additional in-depth research in a larger population of interest.
  • ||||||||||  Actemra SC (tocilizumab SC) / Roche, Halozyme
    Review, Journal:  Biologics for connective tissue diseases and vasculitides (Pubmed Central) -  Feb 8, 2022   
    A phase III trial of the small molecule antagonist avacopan targeting the complement C5a receptor as a replacement for high-dose GC in induction therapy of GPA and MPA met its primary endpoints. Various other biologics and small molecule antagonists are currently in clinical development for several type of vasculitis and collagen vascular diseases, some of them at advanced stages.
  • ||||||||||  Tavneos (avacopan) / Kissei, Vifor, ChemoCentryx, Nucala (mepolizumab) / GSK, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    Journal:  ANCA-associated vasculitis (Pubmed Central) -  Jan 21, 2022   
    As demonstrated in the ADVOCATE-trial avacopan allows for a substantial reduction of glucocorticoid (GC) use during induction of remission...Rituximab is well established as maintenance therapy in AAV...The conception of a predominantly "vasculitis" and a more "eosinophilic" phenotype is supported by this genetic evidence and most likely will lead to more differentiated therapies. With the IL5-antibody mepolizumab a first principle targeting the eosinophilic component of EGPA is now available and proved to be clinically beneficial.
  • ||||||||||  Tavneos (avacopan) / Kissei, Vifor, ChemoCentryx
    EFFECT OF AVACOPAN, A SELECTIVE C5A RECEPTOR INHIBITOR, ON KIDNEY FUNCTION IN PATIENTS WITH ANCA-ASSOCIATED VASCULITIS (Poster Area (Virtual)) -  Jan 21, 2022 - Abstract #ISNWCN2022ISN_WCN_1017;    
    The ADVOCATE Phase 3 trial randomized patients to receive avacopan or prednisone taper on a background of either cyclophosphamide (followed by azathioprine) or rituximab. In ADVOCATE, patients with ANCA-associated vasculitis in the avacopan group had greater recovery of kidney function compared to patients in the prednisone group, especially among patients with CKD Stage 4 and those with eGFR <60 mL/min/1.73 m2 and/or urinary abnormalities at baseline.The material presented in the abstract was submitted to the American Society of Nephrology Kidney Week 2021 and American College of Rheumatology Convergence 2021.
  • ||||||||||  Orencia (abatacept) / BMS
    Review, Journal:  ANCA-Associated Vasculitic Neuropathies: A Review. (Pubmed Central) -  Jan 20, 2022   
    Multidisciplinary approaches are required for the diagnosis and management of the disorder because of its systemic nature. Furthermore, active participation of neurologists is required because the associated neuropathic symptoms can significantly disrupt the day-to-day functioning and quality of life of patients with ANCA-associated vasculitis.
  • ||||||||||  Tavneos (avacopan) / Amgen
    Trial completion, Enrollment change:  ACCOLADE: Controlled Trial Evaluating Avacopan in C3 Glomerulopathy (clinicaltrials.gov) -  Nov 24, 2021   
    P2,  N=57, Completed, 
    The change in C3HI of Disease Chronicity was lower with avacopan compared to placebo and also improved in patients who switched from placebo to avacopan. Active, not recruiting --> Completed | N=88 --> 57
  • ||||||||||  Orencia (abatacept) / BMS
    Review, Journal:  Novel Therapies for ANCA-associated Vasculitis. (Pubmed Central) -  Nov 5, 2021   
    Several studies have been recently published, or are ongoing, to assess the optimal strategy and duration of maintenance of remission with the available treatment options (GC, azathioprine, and RTX)...The management of refractory or relapsing eosinophilic granulomatosis with polyangiitis (EGPA) has been improved by the recent demonstration of efficacy and safety of an interleukin-5 inhibitor, mepolizumab. Ongoing randomised studies will clarify the role of RTX in patients with severe manifestations of EGPA.
  • ||||||||||  Tavneos (avacopan) / Kissei, Vifor, ChemoCentryx
    [VIRTUAL] Effect of Avacopan, a Selective C5a Receptor Inhibitor, on Kidney Function in Patients with ANCA-Associated Vasculitis () -  Oct 24, 2021 - Abstract #ACRCONVERGENCE2021ACR_CONVERGENCE_3444;    
    All patients were randomized to receive prednisone taper or avacopan on a background of either cyclophosphamide (followed by azathioprine) or rituximab. Patients with ANCA-associated vasculitis in the avacopan group had greater recovery of kidney function compared to patients in the prednisone group, especially among patients with chronic kidney disease Stage 4 and those with eGFR < 60 mL/min/1.73 m2 and urinary abnormalities at baseline.
  • ||||||||||  Tavneos (avacopan) / Kissei, Vifor, ChemoCentryx
    [VIRTUAL] Effect of Avacopan, a Selective C5a Receptor Inhibitor, on Kidney Function in Patients with ANCA-Associated Vasculitis (Live-Stream) -  Oct 17, 2021 - Abstract #KIDNEYWEEK2021KIDNEY_WEEK_3923;    
    Urinary albumin:creatinine ratio improved 40% within the first 4 weeks of treatment with avacopan vs. no change in the prednisone group (difference -40, 95% CI [-53, -22]). CONCLUSION In ADVOCATE, patients with ANCA-associated vasculitis in the avacopan group had greater recovery of kidney function compared to patients in the prednisone group, especially among patients with CKD Stage 4 and those with eGFR <60 mL/min/1.73 m2 and/or urinary abnormalities at baseline.
  • ||||||||||  Tavneos (avacopan) / Kissei, Vifor, ChemoCentryx
    [VIRTUAL] Safety and Efficacy of Avacopan (CCX168) in a Pediatric Patient with C3 Glomerulopathy () -  Oct 17, 2021 - Abstract #KIDNEYWEEK2021KIDNEY_WEEK_3818;    
    Case Description An 11-year-old female with biopsy-proven C3GN was initially treated with three intravenous (IV) boluses of methylprednisolone then tapered to oral prednisone (PDN) given with mycophenolate mofetil (MMF) and an angiotensin-converting enzyme inhibitor (ACE-i)...Twelve months following remission, due to relapse of proteinuria (urinary protein/creatinine ratio [UPCR] 1.19 mg/mg), a second course of PDN therapy was started and cyclosporin (CyA) was added to the therapy...At the last follow up (+16 months from open-label start) UPCR was 0.29 mg/mg and the drug was well tolerated. Discussion To the best of our knowledge, this is the first report on the use of avacopan in a pediatric case of C3GN.
  • ||||||||||  Tavneos (avacopan) / Kissei, Vifor, ChemoCentryx
    [VIRTUAL] Complement C5a Receptor in Macrophage-Mediated Renal Inflammation and Fibrosis in Lupus Nephritis () -  Oct 17, 2021 - Abstract #KIDNEYWEEK2021KIDNEY_WEEK_1508;    
    Conclusion C5aR activation induced macrophage secretion of factors that are known to drive inflammation, fibroblast activation and tissue fibrosis, and thus may contribute to LN disease progression. Inhibiting C5aR activity with avacopan blocks these pathological changes, and may provide therapeutic benefit to LN patients.
  • ||||||||||  Tavneos (avacopan) / Kissei, Vifor, ChemoCentryx, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    [VIRTUAL] 9T107: Complement Activation in ANCA-Associated Vasculitis: New Therapeutic Target (Room 2) -  Sep 21, 2021 - Abstract #ACRCONVERGENCE2021ACR_CONVERGENCE_2733;    
    At this session, faculty will discuss the role of complement activation in ANCA-associated vasculitis and the therapeutic potential for targeting this pathway. Learning Objectives: Describe the role of complement in the pathogenesis of ANCA-associated vasculitis Review the data on the efficacy of avacopan in treatment of ANCA-associated vasculitis as well as potential side effects of treatment Discuss the role of avacopan in treatment of ANCA-associated vasculitis, including its potential to replace glucocorticoids